Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLA2G2A | P14555 | 6/20 | 0.67 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.60 |
| ▸ | MEN1 | O00255 | 3/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.60 |
| ▸ | TP53 | P04637 | 2/20 | 0.60 |
| ▸ | MAPT | P10636 | 2/20 | 0.60 |
| ▸ | THRB | P10828 | 1/20 | 0.60 |
| ▸ | DHODH | Q02127 | 3/20 | 0.58 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.56 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.56 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.56 |
| ▸ | HTT | P42858 | 1/20 | 0.56 |
| ▸ | TACR3 | P29371 | 2/20 | 0.55 |
| ▸ | HPGD | P15428 | 3/20 | 0.55 |
| ▸ | GAA | P10253 | 1/20 | 0.54 |
| ▸ | TSHR | P16473 | 1/20 | 0.54 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.54 |
| ▸ | CASP1 | P29466 | 1/20 | 0.54 |
| ▸ | CASP7 | P55210 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27951590 | 0.91 | PLA2G2A (0.80) | PLA2G2AKDM4EALDH1A1MEN1KMT2A | |
| SCHEMBL17923184 | 0.88 | MAPT (0.74) | PLA2G2AKDM4EALDH1A1MEN1KMT2A | |
| SCHEMBL10951942 | 0.86 | KDM4E (0.69) | PLA2G2AKDM4EALDH1A1MEN1KMT2A | |
| SCHEMBL2576382 | 0.86 | KDM4E (0.76) | PLA2G2AKDM4EALDH1A1MEN1KMT2A | |
| SCHEMBL10758450 | 0.86 | TACR3 (0.67) | PLA2G2AKDM4EALDH1A1MEN1KMT2A | |
| SCHEMBL19508615 | 0.86 | PLA2G2A (0.65) | PLA2G2AKDM4EALDH1A1MEN1KMT2A | |
| SCHEMBL16098591 | 0.85 | KDM4E (0.56) | KDM4EALDH1A1MEN1KMT2ATP53 | |
| SCHEMBL1901263 | 0.85 | KDM4E (0.72) | KDM4EALDH1A1TP53DHODHCYP1A2 | |
| SCHEMBL13957862 | 0.84 | LMNA (0.57) | KDM4EALDH1A1TP53MAPTTHRB | |
| SCHEMBL420252 | 0.82 | HPGD (0.72) | KDM4EALDH1A1MEN1KMT2AMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10179770-B2 | Quinolines derivatives as novel anticancer agents | GENOSCIENCE PHARMA (FR) | 2019-01-15 | — | — | US | disclosed |
| US-10179770-B2 | Quinolines derivatives as novel anticancer agents | GENOSCIENCE PHARMA (FR) | 2019-01-15 | — | — | US | disclosed |
| EP-2976333-B1 | QUINOLINES DERIVATIVES AS NOVEL ANTICANCER AGENTS | GENOSCIENCE PHARMA SAS (FR) | 2018-08-08 | — | — | EP | disclosed |
| EP-2976333-B1 | QUINOLINES DERIVATIVES AS NOVEL ANTICANCER AGENTS | GENOSCIENCE PHARMA SAS (FR) | 2018-08-08 | — | — | EP | disclosed |
| US-20160280653-A1 | QUINOLINES DERIVATIVES AS NOVEL ANTICANCER AGENTS | GENOSCIENCE PHARMA (FR) | 2016-09-29 | — | — | US | disclosed |
| US-20160280653-A1 | QUINOLINES DERIVATIVES AS NOVEL ANTICANCER AGENTS | GENOSCIENCE PHARMA (FR) | 2016-09-29 | — | — | US | disclosed |
| US-20160280653-A1 | QUINOLINES DERIVATIVES AS NOVEL ANTICANCER AGENTS | GENOSCIENCE PHARMA (FR) | 2016-09-29 | — | — | US | disclosed |
| EP-2976333-A1 | QUINOLINES DERIVATIVES AS NOVEL ANTICANCER AGENTS | Genoscience Pharma SAS (FR) | 2016-01-27 | — | — | EP | disclosed |
| WO-2014147611-A1 | QUINOLINES DERIVATIVES AS NOVEL ANTICANCER AGENTS | GENOSCIENCE PHARMA (FR) | 2014-09-25 | — | — | WO | disclosed |
| WO-2014147611-A1 | QUINOLINES DERIVATIVES AS NOVEL ANTICANCER AGENTS | GENOSCIENCE PHARMA (FR) | 2014-09-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10179770-B2 | Quinolines derivatives as novel anticancer agents | NQO2, MKI67, NQO1 | PLA2G2A 3134/4885KDM4E 979/4885ALDH1A1 1658/4885 |
| US-20160280653-A1 | QUINOLINES DERIVATIVES AS NOVEL ANTICANCER AGENTS | NQO2, MKI67, NQO1 | PLA2G2A 3134/4885KDM4E 979/4885ALDH1A1 1658/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.